Justin Bowers
Stock Analyst at Deutsche Bank
(2.28)
# 3,202
Out of 4,689 analysts
129
Total ratings
47.6%
Success rate
1.1%
Average return
Main Sectors:
Stocks Rated by Justin Bowers
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CON Concentra Group Holdings Parent | Rated: Buy | $32 → $41 | $34.70 | +18.16% | 3 | Aug 10, 2026 | |
| CRL Charles River Laboratories International | Maintained: Buy | $185 → $300 | $296.41 | +1.21% | 12 | Aug 6, 2026 | |
| WAT Waters | Rated: Hold | $350 → $400 | $421.26 | -5.05% | 11 | Aug 5, 2026 | |
| AVTR Avantor | Maintained: Hold | $25 → $13 | $14.61 | -11.02% | 7 | Jul 30, 2026 | |
| FTRE Fortrea Holdings | Maintained: Hold | $14 → $20 | $18.86 | +6.04% | 7 | Jul 30, 2026 | |
| MEDP Medpace Holdings | Maintained: Hold | $430 → $535 | $611.57 | -12.52% | 4 | Jul 23, 2026 | |
| DHR Danaher | Rated: Buy | $270 → $240 | $215.68 | +11.28% | 11 | Jul 22, 2026 | |
| TMO Thermo Fisher Scientific | Maintained: Buy | $620 → $630 | $630.70 | -0.11% | 10 | Jul 9, 2026 | |
| TECH Bio-Techne | Downgraded: Hold | $66 → $73 | $72.47 | +0.73% | 9 | Jun 26, 2026 | |
| ICLR ICON Public Limited Company | Maintained: Buy | $370 → $188 | $169.72 | +10.77% | 8 | Jun 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $17 → $23 | $64.85 | -64.53% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $6 | $8.37 | -28.32% | 6 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $345 → $315 | $346.09 | -8.98% | 6 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $260 → $220 | $262.38 | n/a | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $155 → $175 | $182.03 | n/a | 8 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $70 | $119.57 | n/a | 1 | Sep 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $140 | $227.69 | n/a | 1 | Jan 17, 2014 |
Concentra Group Holdings Parent
Aug 10, 2026
Rated: Buy
Price Target: $32 → $41
Current: $34.70
Upside: +18.16%
Charles River Laboratories International
Aug 6, 2026
Maintained: Buy
Price Target: $185 → $300
Current: $296.41
Upside: +1.21%
Waters
Aug 5, 2026
Rated: Hold
Price Target: $350 → $400
Current: $421.26
Upside: -5.05%
Avantor
Jul 30, 2026
Maintained: Hold
Price Target: $25 → $13
Current: $14.61
Upside: -11.02%
Fortrea Holdings
Jul 30, 2026
Maintained: Hold
Price Target: $14 → $20
Current: $18.86
Upside: +6.04%
Medpace Holdings
Jul 23, 2026
Maintained: Hold
Price Target: $430 → $535
Current: $611.57
Upside: -12.52%
Danaher
Jul 22, 2026
Rated: Buy
Price Target: $270 → $240
Current: $215.68
Upside: +11.28%
Thermo Fisher Scientific
Jul 9, 2026
Maintained: Buy
Price Target: $620 → $630
Current: $630.70
Upside: -0.11%
Bio-Techne
Jun 26, 2026
Downgraded: Hold
Price Target: $66 → $73
Current: $72.47
Upside: +0.73%
ICON Public Limited Company
Jun 25, 2026
Maintained: Buy
Price Target: $370 → $188
Current: $169.72
Upside: +10.77%
May 8, 2026
Maintained: Hold
Price Target: $17 → $23
Current: $64.85
Upside: -64.53%
May 8, 2026
Maintained: Buy
Price Target: $10 → $6
Current: $8.37
Upside: -28.32%
Feb 13, 2026
Maintained: Buy
Price Target: $345 → $315
Current: $346.09
Upside: -8.98%
Jul 29, 2025
Maintained: Buy
Price Target: $260 → $220
Current: $262.38
Upside: n/a
Aug 16, 2024
Maintained: Buy
Price Target: $155 → $175
Current: $182.03
Upside: n/a
Sep 16, 2019
Initiated Coverage: Hold
Price Target: $70
Current: $119.57
Upside: n/a
Jan 17, 2014
Maintained: Buy
Price Target: $140
Current: $227.69
Upside: n/a